α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: Expression and survival analysis

Konstantin Shilo, Tatiana Dracheva, Haresh Mani, Junya Fukuoka, Isabell A. Sesterhenn, Wei Sing Chu, Joanna H. Shih, Jin Jen, William D. Travis, Teri J. Franks

Research output: Contribution to journalArticle

Abstract

Context. - α-Methylacyl CoA racemase (AMACR) is an oxidative enzyme involved in isomeric transformation of fatty acids entering the beta-oxidation pathway. AMACR serves as a useful marker in establishing a diagnosis of prostatic malignancy; however, limited information is available in regard to its presence in pulmonary neoplasms. Objective. - To investigate AMACR expression within a spectrum of lung carcinomas and its correlation with patients' survival. Design. - Four hundred seventy-seven pulmonary carcinomas, including 150 squamous cell carcinomas, 150 adenocarcinomas, 46 typical carcinoids, 31 atypical carcinoids, 28 large cell neuroendocrine carcinomas, and 72 small cell carcinomas, were studied immunohistochemically using tissue microarray-based samples. Results. - Overall, pulmonary tumors were positive for AMACR in a significant percentage (47%) of cases. Among tumor types, 22% of squamous cell carcinoma, 56% of adenocarcinoma, 72% of typical carcinoid, 52% of atypical carcinoid, 70% of large cell neuroendocrine carcinoma, and 51 % of small cell lung carcinoma were positive for AMACR. Furthermore, the Kaplan-Meier analysis revealed that the patients with AMACR-positive small cell carcinoma had better survival (19% vs 5% after 5 years, P = .04) than patients with AMACR-negative tumors. Such survival advantage was seen for patients with stage I-II (P = .01) but not stage IM-IV small cell carcinomas (P = .58). Conclusions. - These results indicate that, similar to prostate cancer, the overexpression of AMACR frequently occurs in pulmonary carcinomas. Additionally, its positive correlation with outcome of stage I-II small cell lung carcinoma warrants further investigation of the AMACR role in the prognosis of this tumor.

Original languageEnglish (US)
Pages (from-to)1555-1560
Number of pages6
JournalArchives of Pathology and Laboratory Medicine
Volume131
Issue number10
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Racemases and Epimerases
Neuroendocrine Tumors
Coenzyme A
Survival Analysis
Carcinoid Tumor
Squamous Cell Carcinoma
Small Cell Carcinoma
Neuroendocrine Carcinoma
Large Cell Carcinoma
Lung
Small Cell Lung Carcinoma
Neoplasms
Carcinoma
Survival
Adenocarcinoma
Kaplan-Meier Estimate
Lung Neoplasms
Prostatic Neoplasms
Fatty Acids
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Shilo, K., Dracheva, T., Mani, H., Fukuoka, J., Sesterhenn, I. A., Chu, W. S., ... Franks, T. J. (2007). α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: Expression and survival analysis. Archives of Pathology and Laboratory Medicine, 131(10), 1555-1560.

α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors : Expression and survival analysis. / Shilo, Konstantin; Dracheva, Tatiana; Mani, Haresh; Fukuoka, Junya; Sesterhenn, Isabell A.; Chu, Wei Sing; Shih, Joanna H.; Jen, Jin; Travis, William D.; Franks, Teri J.

In: Archives of Pathology and Laboratory Medicine, Vol. 131, No. 10, 10.2007, p. 1555-1560.

Research output: Contribution to journalArticle

Shilo, K, Dracheva, T, Mani, H, Fukuoka, J, Sesterhenn, IA, Chu, WS, Shih, JH, Jen, J, Travis, WD & Franks, TJ 2007, 'α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: Expression and survival analysis', Archives of Pathology and Laboratory Medicine, vol. 131, no. 10, pp. 1555-1560.
Shilo, Konstantin ; Dracheva, Tatiana ; Mani, Haresh ; Fukuoka, Junya ; Sesterhenn, Isabell A. ; Chu, Wei Sing ; Shih, Joanna H. ; Jen, Jin ; Travis, William D. ; Franks, Teri J. / α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors : Expression and survival analysis. In: Archives of Pathology and Laboratory Medicine. 2007 ; Vol. 131, No. 10. pp. 1555-1560.
@article{77eda27d07fe45b086f0b0ef35c23bdf,
title = "α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: Expression and survival analysis",
abstract = "Context. - α-Methylacyl CoA racemase (AMACR) is an oxidative enzyme involved in isomeric transformation of fatty acids entering the beta-oxidation pathway. AMACR serves as a useful marker in establishing a diagnosis of prostatic malignancy; however, limited information is available in regard to its presence in pulmonary neoplasms. Objective. - To investigate AMACR expression within a spectrum of lung carcinomas and its correlation with patients' survival. Design. - Four hundred seventy-seven pulmonary carcinomas, including 150 squamous cell carcinomas, 150 adenocarcinomas, 46 typical carcinoids, 31 atypical carcinoids, 28 large cell neuroendocrine carcinomas, and 72 small cell carcinomas, were studied immunohistochemically using tissue microarray-based samples. Results. - Overall, pulmonary tumors were positive for AMACR in a significant percentage (47{\%}) of cases. Among tumor types, 22{\%} of squamous cell carcinoma, 56{\%} of adenocarcinoma, 72{\%} of typical carcinoid, 52{\%} of atypical carcinoid, 70{\%} of large cell neuroendocrine carcinoma, and 51 {\%} of small cell lung carcinoma were positive for AMACR. Furthermore, the Kaplan-Meier analysis revealed that the patients with AMACR-positive small cell carcinoma had better survival (19{\%} vs 5{\%} after 5 years, P = .04) than patients with AMACR-negative tumors. Such survival advantage was seen for patients with stage I-II (P = .01) but not stage IM-IV small cell carcinomas (P = .58). Conclusions. - These results indicate that, similar to prostate cancer, the overexpression of AMACR frequently occurs in pulmonary carcinomas. Additionally, its positive correlation with outcome of stage I-II small cell lung carcinoma warrants further investigation of the AMACR role in the prognosis of this tumor.",
author = "Konstantin Shilo and Tatiana Dracheva and Haresh Mani and Junya Fukuoka and Sesterhenn, {Isabell A.} and Chu, {Wei Sing} and Shih, {Joanna H.} and Jin Jen and Travis, {William D.} and Franks, {Teri J.}",
year = "2007",
month = "10",
language = "English (US)",
volume = "131",
pages = "1555--1560",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "10",

}

TY - JOUR

T1 - α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors

T2 - Expression and survival analysis

AU - Shilo, Konstantin

AU - Dracheva, Tatiana

AU - Mani, Haresh

AU - Fukuoka, Junya

AU - Sesterhenn, Isabell A.

AU - Chu, Wei Sing

AU - Shih, Joanna H.

AU - Jen, Jin

AU - Travis, William D.

AU - Franks, Teri J.

PY - 2007/10

Y1 - 2007/10

N2 - Context. - α-Methylacyl CoA racemase (AMACR) is an oxidative enzyme involved in isomeric transformation of fatty acids entering the beta-oxidation pathway. AMACR serves as a useful marker in establishing a diagnosis of prostatic malignancy; however, limited information is available in regard to its presence in pulmonary neoplasms. Objective. - To investigate AMACR expression within a spectrum of lung carcinomas and its correlation with patients' survival. Design. - Four hundred seventy-seven pulmonary carcinomas, including 150 squamous cell carcinomas, 150 adenocarcinomas, 46 typical carcinoids, 31 atypical carcinoids, 28 large cell neuroendocrine carcinomas, and 72 small cell carcinomas, were studied immunohistochemically using tissue microarray-based samples. Results. - Overall, pulmonary tumors were positive for AMACR in a significant percentage (47%) of cases. Among tumor types, 22% of squamous cell carcinoma, 56% of adenocarcinoma, 72% of typical carcinoid, 52% of atypical carcinoid, 70% of large cell neuroendocrine carcinoma, and 51 % of small cell lung carcinoma were positive for AMACR. Furthermore, the Kaplan-Meier analysis revealed that the patients with AMACR-positive small cell carcinoma had better survival (19% vs 5% after 5 years, P = .04) than patients with AMACR-negative tumors. Such survival advantage was seen for patients with stage I-II (P = .01) but not stage IM-IV small cell carcinomas (P = .58). Conclusions. - These results indicate that, similar to prostate cancer, the overexpression of AMACR frequently occurs in pulmonary carcinomas. Additionally, its positive correlation with outcome of stage I-II small cell lung carcinoma warrants further investigation of the AMACR role in the prognosis of this tumor.

AB - Context. - α-Methylacyl CoA racemase (AMACR) is an oxidative enzyme involved in isomeric transformation of fatty acids entering the beta-oxidation pathway. AMACR serves as a useful marker in establishing a diagnosis of prostatic malignancy; however, limited information is available in regard to its presence in pulmonary neoplasms. Objective. - To investigate AMACR expression within a spectrum of lung carcinomas and its correlation with patients' survival. Design. - Four hundred seventy-seven pulmonary carcinomas, including 150 squamous cell carcinomas, 150 adenocarcinomas, 46 typical carcinoids, 31 atypical carcinoids, 28 large cell neuroendocrine carcinomas, and 72 small cell carcinomas, were studied immunohistochemically using tissue microarray-based samples. Results. - Overall, pulmonary tumors were positive for AMACR in a significant percentage (47%) of cases. Among tumor types, 22% of squamous cell carcinoma, 56% of adenocarcinoma, 72% of typical carcinoid, 52% of atypical carcinoid, 70% of large cell neuroendocrine carcinoma, and 51 % of small cell lung carcinoma were positive for AMACR. Furthermore, the Kaplan-Meier analysis revealed that the patients with AMACR-positive small cell carcinoma had better survival (19% vs 5% after 5 years, P = .04) than patients with AMACR-negative tumors. Such survival advantage was seen for patients with stage I-II (P = .01) but not stage IM-IV small cell carcinomas (P = .58). Conclusions. - These results indicate that, similar to prostate cancer, the overexpression of AMACR frequently occurs in pulmonary carcinomas. Additionally, its positive correlation with outcome of stage I-II small cell lung carcinoma warrants further investigation of the AMACR role in the prognosis of this tumor.

UR - http://www.scopus.com/inward/record.url?scp=35348991683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348991683&partnerID=8YFLogxK

M3 - Article

C2 - 17922592

AN - SCOPUS:35348991683

VL - 131

SP - 1555

EP - 1560

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 10

ER -